Want to see GB:COG full AI Analyst Report?
Top Page
Cambridge Cognition Holdings
(LSE:COG)
Select Model
Select Model
Rating:44Neutral
Price Target:
27.00 p
▼(-12.90% Downside)
Action:Reiterated
Date:08/06/26
The score is primarily held down by weak financial performance, driven by multi-year operating/net losses and ongoing negative free cash flow (despite improvement in 2025). Technicals are mixed with neutral momentum but a generally weaker longer-term trend, while valuation is constrained by negative earnings and no dividend yield data.
Positive Factors
Strong Gross Margins
Consistently high gross margins indicate that the company’s digital assessment products have attractive underlying economics. If revenue scales without equivalent cost growth, this margin structure could provide a foundation for improved operating leverage and eventual profitability.
Negative Factors
Revenue Below Peak
Revenue remains well below the 2023 peak despite a small 2025 increase, indicating that recent growth has not yet restored the company’s prior scale. A smaller revenue base makes it harder to absorb operating costs and limits the speed at which profitability can improve.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Gross Margins
Consistently high gross margins indicate that the company’s digital assessment products have attractive underlying economics. If revenue scales without equivalent cost growth, this margin structure could provide a foundation for improved operating leverage and eventual profitability.
Read all positive factors
Cambridge Cognition Holdings (COG) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£15.11M
Dividend YieldN/A
Average Volume (3M)14.74K
Price to Earnings (P/E)―
Beta (1Y)1.05
Revenue Growth11.86%
EPS Growth23.81%
CountryUK
Employees74
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.03
Shares Outstanding54,037,327
10 Day Avg. Volume5,002
30 Day Avg. Volume14,737
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)4.06
Price to Sales (P/S)1.29
P/FCF Ratio-46.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)£10.53M
Cambridge Cognition Holdings Business Overview & Revenue Model
Company Description
Cambridge Cognition Holdings Plc is a neuroscience technology company focused on developing and globally marketing sophisticated cognitive testing solutions for use in clinical settings. The firm operates internationally, serving clients in the Un...
Cambridge Cognition Holdings Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
58
Neutral
Cash Flow
27
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.13M | 9.40M | 10.34M | 13.52M | 12.61M | 10.09M |
| Gross Profit | 7.39M | 7.01M | 8.39M | 10.80M | 9.32M | 8.08M |
| EBITDA | -716.00K | -960.00K | -542.00K | -2.62M | -514.00K | 412.00K |
| Net Income | -1.40M | -1.68M | -1.78M | -3.51M | -409.00K | 450.00K |
Balance Sheet | ||||||
| Total Assets | 11.31M | 11.28M | 13.03M | 14.23M | 15.11M | 12.54M |
| Cash, Cash Equivalents and Short-Term Investments | 582.00K | 1.13M | 1.30M | 3.23M | 8.32M | 6.81M |
| Total Debt | 239.00K | 873.00K | 1.91M | 2.56M | 18.00K | 18.00K |
| Total Liabilities | 9.12M | 8.29M | 9.67M | 12.95M | 15.01M | 11.91M |
| Stockholders Equity | 2.19M | 2.99M | 3.36M | 1.28M | 95.00K | 632.00K |
Cash Flow | ||||||
| Free Cash Flow | 380.00K | -262.00K | -3.09M | -5.00M | 1.49M | 3.88M |
| Operating Cash Flow | 421.00K | -232.00K | -3.08M | -4.97M | 1.68M | 3.93M |
| Investing Cash Flow | -41.00K | -30.00K | 50.00K | -3.02M | -189.00K | -105.00K |
| Financing Cash Flow | 0.00 | 152.00K | 1.13M | 2.88M | -132.00K | -86.00K |
Cambridge Cognition Holdings Technical Analysis
Neutral
31.00
Price Trends
28.71
Negative
30.98
Negative
34.05
Negative
Market Momentum
-0.21
Negative
47.13
Neutral
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:COG, the sentiment is Neutral. The current price of 31 is above the 20-day moving average (MA) of 27.92, above the 50-day MA of 28.71, and below the 200-day MA of 34.05, indicating a neutral trend. The MACD of -0.21 indicates Negative momentum. The RSI at 47.13 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:COG.
Cambridge Cognition Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | £68.95M | 11.49 | 17.74% | ― | -6.51% | 108.62% | |
62 Neutral | £172.63M | -635.94 | -0.68% | ― | 20.14% | 82.22% | |
61 Neutral | £25.73M | -5.99 | -16.18% | ― | 13.04% | 15.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | £15.11M | -9.30 | -54.17% | ― | 11.86% | 23.81% | |
43 Neutral | £10.23M | -9.83 | -46.61% | ― | 28.35% | 57.14% | |
40 Underperform | £14.18M | -0.26 | -451.74% | ― | 33.37% | 86.41% |
* Healthcare Sector Average
GB:COG
Cambridge Cognition Holdings
28.00
-6.00
-17.65%
GB:IXI
IXICO plc
11.75
0.50
4.44%
GB:OBD
Oxford BioDynamics
0.11
-0.22
-67.19%
GB:KOO
Kooth
189.50
57.50
43.56%
GB:DXRX
Diaceutics
203.50
42.00
26.01%
GB:APTA
Aptamer Group Plc
0.30
-0.55
-65.29%
Cambridge Cognition Holdings Corporate Events
Business Operations and Strategy
Cambridge Cognition joins NHS study to bring earlier Alzheimer’s diagnosis into primary care
Positive
Oct 6, 2026
Cambridge Cognition Holdings has joined a major NHS-backed study led by Imperial College London to bring earlier Alzheimer’s diagnosis into primary care using its CANTAB digital cognitive assessments. The BEAD-PC project will recruit 500 pat...
Business Operations and Strategy
Cambridge Cognition chair boosts stake with share purchase
Positive
Sep 23, 2026
Cambridge Cognition Holdings reported that its non-executive chair, Nick Rodgers, purchased 19,000 ordinary shares in the company at 27.4 pence per share on 18 September, increasing his holding to 98,892 shares, or about 0.18% of the company’...
Business Operations and StrategyProduct-Related Announcements
Cambridge Cognition and C2N Join Alzheimer’s Trust in U.K. Diagnostic Push
Positive
Sep 21, 2026
C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated diagnostic pathway for Alzheimer’s disease across the U.K., combining C2N’s MHRA-registered PrecivityAD2 blood test with Ca...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Cambridge Cognition posts revenue growth, strengthens balance sheet in H1 2026
Positive
Sep 16, 2026
Cambridge Cognition reported a solid first half of 2026, with revenue rising 16% to £5.0m and gross profit up 21%, driven mainly by clinical study work and supported by maiden income from healthcare and consumer wellness pilots. The company i...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.